A Systematic Overview of Chemotherapy Effects in Ovarian Cancer

References

• National Board of Health and Welfare-Centre for Epidemi-ology. Cancer Incidence in Sweden 1998. Stockholm: Social-styrelsen 2000. (0*)
   Google Scholar
• The National Board of Health and Welfare-Centre for Epi-demiology. Causes of Death 1997. Stockholm: Statistiska centralbyrän 2000. (0*)
   Google Scholar
• Banks E, Beral V, Reeves G. The epidemiology of epithelial ovarian cancer: a review. Int .1- Gynecol Cancer 1997; 7 (6): 425–38. (0*)
   Google Scholar
• Adami HO, Bergstrom R, Persson I, et al. The incidence of ovarian cancer in Sweden, 1960-1984. Am J Epidemiol 1990; 132: 446-52. (0*)
   Google Scholar
• Riman T, Persson I, Nilsson S. Hormonal aspects of epithe-lial ovarian cancer: review of epidemiological evidence. Chin Endocrinol 1998; 49: 695-707. (0*)
   Google Scholar
• Engeland A, Haldorsen T, Tretli S, et al. Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. APMIS 1993; 101 (Suppl 38): 1–124. (0*)
   Google Scholar
• Hogberg T, Anderson H. Better prognosis in epithelial ovarian cancer. Läkartidningen 1997; 94: 28-31. (0*)
   Google Scholar
• Bjorkholm E, Pettersson F, Einhom N, et al. Long-term follow-up and prognostic factors in ovarian carcinoma. The Radiumhemmet series 1958 to 1973. Acta Radiol Oncol 1982; 21: 413–9. (R*)
   Google Scholar
• Einhom N, Nilsson B, Sjovall K. Factors influencing sur-vival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 1985; 55: 2019–25. (R*)
   Google Scholar
• Hogberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithe-lial ovarian cancer. Gynecol Oncol 1993; 48: 38–49. (R*)
   Google Scholar
• Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant epithelial tumors. Gynecol Oncol 1983; 25: 370–80. (R*)
   Google Scholar
• Bjorge T, Engeland A, Hansen S, et al. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int .1- Cancer 1998; 75: 663–70. (0*)
   PubMedGoogle Scholar
• Bjorge T, Engeland A, Sundfor K, et al. Prognosis of 2 800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand 1998; 77: 777-81. (0*)
   PubMedGoogle Scholar
• Marsoni S, Toni W, Taiana A, et al. Critical review of the quality and development of randomized clinical trials (RCTs) and their influence on the treatment of advanced epithelial ovarian cancer. Ann Oncol 1990; 1: 343-50. (0*)
   Google Scholar
• Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-72. (C1/186)
   Google Scholar
• Trope C, Andersson H, Bjorkholm E, et al. Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer - ten-year survival results from a prospective ran-domized study by the Swedish Cooperative Ovarian Cancer Study Group. Acta Oncol 1996; 35 (Suppl 8): 109–18. (C1/300)
   Google Scholar
• Pettersson F. Annual report on the results of treatment in gynecological cancer. Stockholm: Radiumhemmet, 1996: 22. (0*)
   Google Scholar
• Pettersson F. Annual report on the results of treatment in gynaecological cancer. Stockholm: Radiumhemmet, 1985: 19. (0*)
   Google Scholar
• Trimble EL, Kaern J, Trope C. Management of borderline tumors of the ovary. In: Gershenson DM, McGuire WP, eds. Ovarian cancen controversies in management. New York: Churchill Livingstone Inc, 1998: 195–218. (R*)
   Google Scholar
• Trope C. Prognostic factors in ovarian cancer. In: Ozols RF, ed. Gynecologic Oncology Cancer Treatment and Research. Boston: Kluwer Academic Publishers, 1998: 287–352. (L*)
   Google Scholar
• van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. New Engl J Med 1995; 332: 629-34. (C1/319)
   Google Scholar
• Ahmed FY, Wiltshaw E, A'Hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian car-cinoma. J Clin Oncol 1996; 14: 2968-75. (P1/194)
   Google Scholar
• Monga M, Carmichael JA, Shelley WE, et al. Surgery with-out adjuvant chemotherapy for early epithelial ovarian car-cinoma after comprehensive surgical staging. Gynecol Oncol 1991; 43: 195-7. (P1/82)
   Google Scholar
• Trimbos JB, Schueler JA, van der Burg M, et al. Watch and wait after careful surgical treatment and staging in well-dif-ferentiated early ovarian cancer. Cancer 1991; 67: 597-602. (P1/67)
   Google Scholar
• Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: Results of two ran-domised clinical trials comparing cisplatin to no further treatment or chromic phosphate (P-32). Ann Oncol 1995; 6: 887-93. (C1/271)
   Google Scholar
• Davy M, Stenwig AE, Kjorstad KE, et al. Early stage ovarian cancer. The effect of adjuvant treatment with a single alkylating agent. Acta Obstet Gynecol Scand 1985; 64: 531–2. (C*)
   Google Scholar
• Dembo AJ, Bush RS, Beale FA, et al. Ovarian carcinoma: improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol 1979; 134: 793–800. (C*)
   PubMed Web of Science ®Google Scholar
• Dembo AJ. The role of radiotherapy in ovarian cancer. Bull Cancer (Paris) 1982; 69: 275-83. (C2/147)
   Google Scholar
• Gronroos M, Nieminen U, Kauppila A, et al. A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation. Eur J Obstet Gynecol Reprod Biol 1984; 17: 33–42. (C*)
   PubMedGoogle Scholar
• Hreshchyshyn MM, Park RC, Blessing JA, et al. The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol 1980; 138: 139–45. (C*)
   PubMed Web of Science ®Google Scholar
• Klaassen D, Shelley W, Starreveld A, et al. Early stage ovarian cancer - a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperi-toneal chromic phosphate - a National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 1988; 6: 1254-63. (C2/284)
   Google Scholar
• Kolstad P, Davy M, Hoeg K. Individualized treatment of ovarian cancer. Am J Obstet Gynecol 1977; 128: 617–25. (C*)
   PubMedGoogle Scholar
• Redman CW, Mould J, Warwick J, et al. The West Mid-lands epithelial ovarian cancer adjuvant therapy trial. Clin Oncol (R Coll Radiol) 1993; 5: 1–5. (C*)
   PubMedGoogle Scholar
• Sell A, Bertelsen K, Andersen JE, et al. Randomized study of whole-abdomen irradiation vs pelvic irradiation plus cy-clophosphamide in treatment of early ovarian cancer. Gy-necol Oncol 1990; 37: 367-73. (C1/412)
   Google Scholar
• Sigurdsson K, Johnsson JE, Trop8 C. Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy. Ann Chir Gynaecol 1982; 71: 321–9. (C*)
   Google Scholar
• Smith JP, Rutledge FN, Delclos L. Postoperative treatment of early cancer of the ovary: a random trial between postop-erative irradiation and chemotherapy. Natl Cancer Inst Monogr 1975; 42: 149-53. (C3/156)
   Google Scholar
• Trope C, Kaern J, Hogberg T, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000; 11: 1-8. (C1/175)
   Google Scholar
• Vergote IB, Vergote-de Vos LN, Abeler VM, et al. Random-ized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741-9. (C1/347)
   Google Scholar
• Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-7. (C2/237)
   Google Scholar
• Young RC, Brady MF, Nieberg RM, et al. Randomized clinical trial of adjuvant treatment of women with early (FIGO MIA high risk) ovarian cancer - GOG # 95. Int .1- Gynecol Cancer 1999; 9 (Suppl 1): 11. Abstr A33. (C1/251)
   Google Scholar
• Bolis G, Bortolozzi G, Carinelli G, et al. Low-dose cy-clophosphamide vs adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study. Can-cer Chemother Pharmacol 1980; 4: 129–32. (C**)
   PubMedGoogle Scholar
• Dent SF, Klaassen D, Pater JL, et al. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol 2000; 11: 65-8. (C2/284)
   Google Scholar
• Trope C, Hogberg T, Kaern J, et al. Long-term results from a phase II study of single agent paclitaxel (Taxol) in previ-ously platinum treated patients with advanced ovarian can-cer: the Nordic experience. Ann Oncol 1998; 9: 1301-7. (P1/136)
   Google Scholar
• Murphy D, Crowther D, Renninson J, et al. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four-week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 1993; 4: 377-83. (C1/99)
   Google Scholar
• Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991; 303: 884–893. (M1/5 667)
   Google Scholar
• Aabo K, Hald I, Horbov S, et al. A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. Eur J Cancer Clin Oncol 1985; 21: 475–81. (C**)
   PubMedGoogle Scholar
• Adams M, Kerby U, Rocker I, et al. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol 1989; 28: 57–60. (C**)
   Google Scholar
• Alberts DS, Green S, Hannigan EV, et al. Improved thera-peutic index of carboplatin plus cyclophosphamide vs cis-platin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706–17. (C**)
   PubMed Web of Science ®Google Scholar
• Anderson H, Wagstaff J, Crowther D, et al. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 1988; 249: 1471–9. (C**)
   Google Scholar
• Bell DR, Woods RL, Levi JA, et al. Advanced ovarian cancer: a prospective randomised trial of chlorambucil vs combined cyclophosphamide and cis-diamminedichloroplat-inum. Aust N Z J Med 1982; 12: 245–9. (C**)
   PubMedGoogle Scholar
• ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, et al. Carboplatin in combination therapy for ovarian cancer. Cancer Treatm Rev 1988; 15 (Suppl B): 9–15. (C**)
   Google Scholar
• Brodovsky HS, Bauer M, Horton J, et al. Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer. Cancer 1984; 53: 844–52. (C**)
   PubMed Web of Science ®Google Scholar
• Bruckner HW, Pagano M, Falkson G, et al. Controlled prospective trial of combination chemotherapy with cy-clophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report. Cancer Treatm Rep 1979; 63: 297–9. (C**)
   PubMedGoogle Scholar
• Chylak V, Kolaric K, Krusic J. Controlled prospective study of chemotherapy in advanced ovarian cancer-cyclophos-phamide monochemotherapy vs polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate. Lijec Vjesn 1987; 109: 230–4. (C**)
   Google Scholar
• Cohen CJ, Goldberg JD, Holland JF, et al. Improved ther-apy with cisplatin regimens for patients with ovarian car-cinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). Am J Obstet Gynecol 1983; 145: 955–67. (C**)
   PubMedGoogle Scholar
• Conte PF, Bruzzone M, Camino F, et al. Carboplatin, doxorubicin, and cyclophosphamide vs cisplatin, doxoru-bicin, and cyclophosphamide: a randomized trial in stage UI-IV epithelial ovarian carcinoma. J Clin Oncol 1991; 9: 658–63. (C**)
   PubMed Web of Science ®Google Scholar
• Decker DG, Fleming TR, Malkasian GD, et al. Cyclophos-phamide plus cis-platinum in combination: treatment pro-gram for stage III or IV ovarian carcinoma. Obstet Gynecol 1982; 60: 481–7. (C**)
   PubMed Web of Science ®Google Scholar
• Edmonson JH, Fleming TR, Decker DG, et al. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma vs minimal resid-ual disease. Cancer Treatm Rep 1979; 63: 241–7. (C**)
   PubMedGoogle Scholar
• Edmonson JH, McCormack GM, Wieand HS, et al. Cy-clophosphamide-cisplatin vs cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J Natl Cancer Inst 1989; 81: 1500–4. (C**)
   PubMedGoogle Scholar
• Gruppo Interregionale Cooperativo Oncologico Ginecolo-gia. Randomised comparison of cisplatin with cyclophos-phamide/cisplatinandwithcyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Lancet 1987;2: 353–9. (C**)
   Google Scholar
• Gynaecological Group, Clinical Oncological Society of Aus-tralia and the Sydney Branch, Ludwig Institute for Cancer Research. Chemotherapy of advanced ovarian adenocar-cinoma: a randomized comparison of combination vs se-quential therapy using chlorambucil and cisplatin. Gynecol Oncol 1986;23:1-13 (C**)
   Google Scholar
• Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997; 15: 193-8. (C1/222)
   Google Scholar
• Kato T, Nishimura H, Yamabe T, et al. Phase III study of carboplatin in ovarian cancer. Gan To Kagaku Ryoho 1988; 15: 2297–304. (C**)
   PubMedGoogle Scholar
• Mangioni C, Bolis G, Pecorelli S, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carbo-platin. J Natl Cancer Inst 1989; 81: 1464–71. (C**)
   PubMedGoogle Scholar
• Masding J, Sarkar TK, White WF, et al. Intravenous treosulfan vs intravenous treosulfan plus cisplatinum in ad-vanced ovarian carcinoma. Br J Obst Gynaecol 1990; 97: 342–51. (C**)
   PubMedGoogle Scholar
• Medical Research Council Working Party on Ovarian Can-cer. Medical Research Council study on chemotherapy in advanced ovarian cancer. Br J Obst Gynaecol 1981; 88: 1174–85. (C**)
   Google Scholar
• Miller AB, Klaassen DJ, Boyes DA, et al. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. Can Med Assoc J 1980; 123: 365–71. (C**)
   Google Scholar
• de Oliveira CF, Lacave AJ, Villani C, et al. Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) vs cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study. Eur J Gynaecol Oncol 1990; 11: 323–30. (C**)
   PubMedGoogle Scholar
• Omura GA, Morrow CP, Blessing JA, et al. A randomized comparison of melphalan vs melphalan plus hexamethylme-lamine vs adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983; 51: 783–9. (C**)
   PubMed Web of Science ®Google Scholar
• Omura GA, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986; 57: 1725–30. (C**)
   Google Scholar
• Omura GA, Bundy BN, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxoru-bicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989; 7: 457–65. (C**)
   PubMed Web of Science ®Google Scholar
• Park RC, Blom J, DiSaia PJ, et al. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorou-racil and dactinomycin. Cancer 1980; 45: 2529–42. (C**)
   PubMed Web of Science ®Google Scholar
• Pater J. Cyclophosphamide (C)/cisplatin (CDDP) vs cy-clophosphamide/carboplatin (CBDCA) in macroscopic residual ovarian cancer. Initial results of a National Clinical Trials Group trial. Proc Am Soc Clin Oncol 1990; 9: 155 Abstr 602. (C**)
   Google Scholar
• Sturgeon JF, Fine S, Gospodarowiez MK, et al. A ran-domised trial of melphalan alone vs. combination chemotherapy in advanced ovarian cancer. Proc Am Soc Clin Oncol 1982; 1: 108. Abstr C-418. (C**)
   Google Scholar
• Tomirotti M, Perrone S, Gi8 P, et al. Cisplatin (P) vs cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective random-ized trial. Tumori 1988; 74: 573–7. (C**)
   Google Scholar
• Trope C. Melphalan with and without doxorubicin in ad-vanced ovarian cancer. Obstet Gynecol 1987; 70: 582–6. (C**)
   Google Scholar
• Turbow MM, Jones H, Yu VK, et al. Chemotherapy of ovarian carcinoma: a comparison of melphalan vs. adri-amycin-cyclophosphamide. Proc Am Soc Cancer Res Am Soc Clin Oncol 1980; 21: 196 Abstr. (C**)
   Google Scholar
• Vogl S, Kaplan B, Pagano M. Diamminedichloroplatinum-based combination chemotherapy is superior to melphalan for advanced ovarian cancer when age 50 and tumor diameter 2 cm. Proc Am Soc Clin Oncol 1982; 1: 119 Abstr C-462. (C**)
   Google Scholar
• Wharton JT, Edwards CL, Rutledge FN. Long-term survival after chemotherapy for advanced epithelial ovarian car-cinoma. Am J Obstet Gynecol 1984; 148: 997–1005. (C**)
   Google Scholar
• Wilbur DW, Rentschler RE, Wagner RJ, et al. Randomized trial of the addition of cis-platin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian car-cinoma. J Surg Oncol 1987; 34: 165–9. (C**)
   PubMed Web of Science ®Google Scholar
• Williams CJ, Mead GM, Macbeth FR, et al. Cisplatin combination chemotherapy vs chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol 1985; 3: 1455–62. (C**)
   PubMed Web of Science ®Google Scholar
• Wiltshaw E, Evans B, Harland S. Phase III randomised trial cisplatin vs JM8 (carboplatin) in 112 ovarian cancer patients, stages III and W. Proc Am Soc Clin Oncol 1985; 4: 121. (C**)
   Google Scholar
• Wiltshaw E, Evans B, Austin G, et al. A prospective ran-domized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 1986; 4: 722–9. (C**)
   PubMed Web of Science ®Google Scholar
• Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78: 1479–87. (M1/8 139)
   Google Scholar
• Athanassiou A, Pectasides D, Varthalitis J, et al. Carbo-platin (C) vs C ifosfamide (I) ± vincristine (V) ± bleomycin (B) in epithelial ovarian cancer (OC). Ann Oncol ;(Suppl) 1990; 1: 2–25. (C**)
   Google Scholar
• Gennatas C, Alamanos J, Dardoufas C, et al. Carboplatin, epirubicin and cyclophosphamide vs cisplatin, epirubicin and cyclophosphamide: a phase III randomised trial in stages III and W epithelial ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 227 Abstr 720. (C**)
   Google Scholar
• Skarlos DV, Aravantinos G, Kosmidis P, et al. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A Hellenic Co-operative Oncology Group study. Eur J Cancer 1996; 32A: 421–8. (C**)
   Google Scholar
• Leonard RC, Smart GE, Livingstone JR, et al. Randomised trial comparing prednimustine with combination chemother-apy in advanced ovarian carcinoma. Cancer Chemother Pharmacol 1989; 23: 105–10. (C**)
   PubMedGoogle Scholar
• Wadler S, Yeap B, Vogl S, et al. Randomized trial of initial therapy with melphalan vs cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long-term results - Eastern cooperative oncol-ogy group study E2878. Cancer 1996; 77: 733–42. (C**)
   PubMedGoogle Scholar
• Lokich J, Anderson N. Carboplatin vs cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9: 13-21. (0*)
   Google Scholar
• The Ovarian Cancer Meta-Analysis Project. Cyclophos-phamide plus cisplatin vs cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668–74. (M1/1 194)
   Google Scholar
• Bertelsen K, Jakobsen A, Andersen JE, et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161–9. (C**)
   PubMed Web of Science ®Google Scholar
• Conte PF, Bruzzone M, Chiara S, et al. A randomized trial comparing cisplatin plus cyclophosphamide vs cisplatin, dox-orubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4: 965–71. (C***)
   PubMed Web of Science ®Google Scholar
• Hernadi Z, Juhasz B, Poka R, et al. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer. Int .1- Gynaecol Obstet 1988; 27: 199–204. (C**)
   PubMed Web of Science ®Google Scholar
• The Ovarian Cancer Meta-Analysis Project. Cyclophos-phamide plus cisplatin vs cyclophosphamide, doxorubicine and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. Classic Papers and Current Comments 1998; 3: 237-43. (M1*)
   Google Scholar
• A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32. (M1)
   PubMedGoogle Scholar
• Gore ME, Levy V, Austin G, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016-9. (P1/155)
   Google Scholar
• Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cis-platin, doxorubicin, and cyclophosphamide vs cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Ob-stet Gynecol 1992; 80: 954-60. (M2/2059)
   Google Scholar
• West RJ, Zweig SF. Meta-analysis of chemotherapy regi-mens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin vs cisplatin and cy-clophosphamide. Eur J Gynaecol Oncol 1997; 18: 343-8. (M2 /4197)
   Google Scholar
• The ICON Collaborators. ICON2: randomised trial of sin-gle-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. Interna-tional Collaborative Ovarian Neoplasm Study. Lancet 1998; 352: 1571-6. (C1/1526)
   Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56. (R*)
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophos-phamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage W ovarian cancer. N Engl J Med 1996; 334: 1-6. (C1/410)
   Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Long-term follow-up of GOG-111: a randomized trial comparing cis-platin combined with cyclophosphamide or paclitaxel in patients with stage III or IV epithelial ovarian cancer. Int .1-Gynecol Cancer 1999; 9 (Suppl 1): 8 Abstr A24. (C1*)
   Google Scholar
• Piccart MJ, Bertelsen K, James K, et al. Randomized inter-group trial of cisplatin-paclitaxel vs cisplatin-cyclophos-phamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708. (C1/680)
   Google Scholar
• Harper P. A randomised comparison of paclitaxel (T) and carboplatin (J) vs control arm of single agent carboplatin(J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients randomised into 3rd International Collabora-tive Ovarian Neoplasm Study (ICON3). Proc Am Soc Clin Oncol 1999; 18: 356 Abstr 1375. (C1/2 074)
   Google Scholar
• Muggia FM, Braly PS, Brady MF, et al. Phase III Random-ized Study of Cisplatin Vs Paclitaxel Vs Cisplatin and Pacli-taxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2000; 18: 106. (C2/648)
   Google Scholar
• Colombo N. Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) vs a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin & cisplatin) The third International Collaborative Ovarian Neoplasms Study (ICON3). Proc Am Soc Clin Oncol 2000; 19: 379a Abstr 1500. (C*)
   Google Scholar
• Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) vs Carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 1999; 18: 365a Abstr 1373. (C1/798)
   Google Scholar
• du Bois A, Luck HJ, Buser K, et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. Eur J Cancer 1997; 33: 379-84. (P1/112)
   Google Scholar
• Neijt JP, Hansen M, Hansen SW, et al. Randomized phase III study in prerviously untreated epithelial ovarian cancer FIGO stage 11B, IIC, III, W, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol 1997; 16: 352a Abstr 1259. (C2/190)
   Google Scholar
• Mobus V, Provencal J, du Bois A, et al. Epirubicin/pacli-taxel/carboplatin vs. paclitaxel/carboplatin as first-line treat-ment in ovarian cancer: updated results of a safety interim analysis of the AGO-GINECO intergroup trial. Int .1- Gy-necol Cancer 1999; 9 (Suppl 1): 48 Abstr A145. (C1/722)
   Google Scholar
• Malmstrom H. Intraperitoneal chemotherapy of ovarian cancer. Linkoping University Medical Dissertations. Thesis no 376, 1993. (0*)
   Google Scholar
• Los G, Verdegaal EM, Mutsaers PH, et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991; 28: 159-65. (0*)
   PubMedGoogle Scholar
• Burghardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40: 103-6. (0*)
   PubMedGoogle Scholar
• Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide vs intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5. (C2/654)
   Google Scholar
• Gadducci A, Camino F, Chiara S, et al. Intraperitoneal vs intravenous cisplatin in combination with intravenous cy-clophosphamide and epidoxorubicin in optimally cytore-duced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologic° Nord-Ovest. Gynecol Oncol 2000; 76: 157-62. (C2/113)
   Google Scholar
• Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 2620-4. (P1/80)
   Google Scholar
• Markman M, Bundy B, Benda J, et al. Randomized phase 3 study of intravenous (W) cisplastin (CIS)/paclitaxel (PAC) vs moderately high dose IV carboplatin (CARB) followed by W PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): an intergroup trial (GOG, SWOG, ECOG). Proc Am Soc Clin Oncol 1998; 17: 361 Abstr 1392. (C2/523)
   Google Scholar
• Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756–67. (R*)
   PubMed Web of Science ®Google Scholar
• Levin L, Simon R, Hryniuk W. Importance of Multiagent Chemotherapy Regimens in Ovarian Carcinoma-Dose Inten-sity Analysis. J Natl Cancer Inst 1993; 85: 1732–42. (R*)
   Google Scholar
• Behrens BC, Hamilton TC, Masuda H, et al. Characteriza-tion of a cis-iamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987; 47: 414-8. (0*)
   PubMedGoogle Scholar
• Torn i V, Simon R, Russek-Cohen E, et al. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J Natl Cancer Inst 1992; 84: 407-14. (0*)
   Google Scholar
• Repetto L, Pace M, Mammoliti S, et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 1993; 29A: 181-4. (R1/226)
   Google Scholar
• Conte PF, Bruzzone M, Camino F, et al. High-dose vs low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A ran-domized study of the Gruppo Oncologic° Nord-Ovest. J Clin Oncol 1996; 14: 351-6. (C1/145)
   Google Scholar
• Gore M, Mainwaring P, Hem R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998; 16: 2426-34. (C1/227)
   Google Scholar
• Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33. (C1/159)
   Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 1589-99. (C1/485)
   Google Scholar
• Ngan HY, Choo YC, Cheung M, et al. A randomized study of high-dose vs low-dose cis-platinum combined with cy-clophosphamide in the treatment of advanced ovarian can-cer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy 1989; 35: 221-7. (C2/65)
   Google Scholar
• Ngan HY, Cheng DK, Ng TY, et al. Long-term survival analysis of high dose vs low dose cis-platinum combined with cyclophosphamide in advanced ovarian cancer. Int J Gynecol Cancer 1999; 9 (Suppl 1): 22 Abstr A65. (C*)
   Google Scholar
• Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996; 14: 2113–9. (C*)
   PubMed Web of Science ®Google Scholar
• Colombo N, Pittelli MR, Parma G, et al. Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): a randomized study of conventional dose (DC) vs dose-intense (DI) cis-platin chemotherapy. Proc Am Soc Clin Oncol 1993; 12: 255 Abstr 806. (C2/306)
   Google Scholar
• Cocconi G, Bella M, Lottici R, et al. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma. Am J Clin Oncol 1999; 22: 559-67. (C2/101)
   Google Scholar
• Horowitz MM, Stiff PJ, Veum-Stone J, et al. Outcome of autotransplants for advanced ovarian cancer. Proc Am Soc Clin Oncol 1997; 16: 353 Abstr 1262 (R2/421)
   Google Scholar
• Hogberg T, Simonsen E, Carstensen J. A population-based survey of ovarian malignancies in the southeast health care region of Sweden 1984-1987. Acta Oncol 1994; 33: 739–45. (R*)
   Google Scholar
• Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatinum. J Clin Oncol 1991; 9: 389–93. (P*)
   PubMed Web of Science ®Google Scholar
• Austin GJ, Nelstrop AE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997; 15: 172-6. (P1/66)
   Google Scholar
• Markman M. Prognostic factors in salvage therapy of ovarian cancer. Ann Oncol 1997; 8: 937–8. (R*)
   PubMedGoogle Scholar
• Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pre-treated ovarian cancer: a multivariate analysis of 704 pa-tients. Ann Oncol 1997; 8: 963–8. (R*)
   Google Scholar
• Hogberg T, Kagedal B. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125. Gy-necol Oncol 1992; 46: 191–8. (P*)
   PubMedGoogle Scholar
• Ozols RF. Treatment of recurrent ovarian cancer: increasing options - "recurrent" results. J Clin Oncol 1997; 15: 2177–80. (L*)
   PubMedGoogle Scholar
• van der Velden J, Gitsch G, Wain GV, et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int .1- Gy-necol Cancer 1995; 5: 301–5. (P*/30)
   PubMed Web of Science ®Google Scholar
• Manetta A, MacNeill C, Lyter JA, et al. Hexamethylme-lamine as a single second-line agent in ovarian cancer. Gynecol Oncol 1990; 36: 93-6. (P1/52)
   Google Scholar
• Moore DH, Fowler WC, Jones CP, et al. Hexamethylme-lamine chemotherapy for persistent or recurrent epithelial ovarian cancer. Am J Obstet Gynecol 1991; 165: 573-6. (P1/25)
   Google Scholar
• Moore DH, Valea F, Crumpler LS, et al. Hexamethylme-lamine/altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 1993; 51: 109-12. (P1/44)
   Google Scholar
• Rosen GF, Lurain JR, Newton M. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Gynecol Oncol 1987; 27: 173-9. (P1/20)
   Google Scholar
• Vergote I, Himmelmann A, Frankendal B, et al. Hexam-ethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992; 47: 282-6. (P1/61)
   Google Scholar
• ten Bokkel Huinink WW, Gore M, Carmichael J, et al. Topotecan vs paclitaxel for the treatment of recurrent epithe-lial ovarian cancer. J Clin Oncol 1997; 15: 2183-93. (C1/226)
   Google Scholar
• Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 3056-61. (P1/111)
   Google Scholar
• Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-7. (P1/28)
   Google Scholar
• Swisher EM, Mutch DG, Rader JS, et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66: 480-6. (P1/28)
   Google Scholar
• Aravantinos G, Skarlos DV, Kosmidis P, et al. A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study. Eur J Cancer 1997; 33: 160-3. (P1/51)
   Google Scholar
• Baker TR, Piver MS, Hempling RE. Response to Taxol chemotherapy in resistant ovarian carcinoma. Eur J Gy-naecol Oncol 1993; 14: 449-54. (P1/25)
   Google Scholar
• du Bois A, Lueck HJ, Meier W, et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update on an Ar-beitsgemeinschaft Gynaekologische Onkologie (AGO) study group trial. Proc Am Soc Clin Oncol 1999; 18: 356 Abstr 1374. (C1/798)
   Google Scholar
• Bruzzone M, Catsafados E, Miglietta L, et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology 1996; 53: 349-53. (P1/39)
   Google Scholar
• Einzig Al, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for ad-vanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-53. (P1/34)
   Google Scholar
• Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose vs low-dose and long vs short infusion. J Clin Oncol 1994; 12: 2654-66. (C1/407)
   Google Scholar
• Ezcurdia L, Jovtis SL, Mickiewicz E, et al. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multi-center Taxol Group. Semin Oncol 1997; 24 (Suppl 15): 15. (P1/37)
   Google Scholar
• Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24. (P1/44)
   Google Scholar
• Mayerhofer K, Kucera E, Zeisler H, et al. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol 1997; 64: 109-13. (P1/28)
   Google Scholar
• McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in ad-vanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9. (P1/47)
   Google Scholar
• Nardi M, Aloe A, De Marco S, et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol 1997; 20: 230-2. (P1/33)
   Google Scholar
• Planner RS, Allen DG, Brand AH, et al. Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer. Aust N Z J Obstet Gynaecol 1996; 36: 168-70. (P1/31)
   Google Scholar
• Seewaldt VL, Greer BE, Cain JM, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 1994; 170: 1666-70. (P1/100)
   Google Scholar
• Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-53. (P1/45)
   Google Scholar
• Trimble EL, Adams JD, Vena D, et al. Paclitaxel for plat-inum-refractory ovarian cancer: results from the first 1 000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405-10. (P1/1000)
   Google Scholar
• Uziely B, Groshen S, Jeffers S, et al. Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol 1994; 5: 827-33. (P1/68)
   Google Scholar
• Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12: 2301-8. (P1/25)
   Google Scholar
• Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur J Cancer 1997; 33: 2167-70. (P1/340)
   Google Scholar
• Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60-3. (P1/31)
   Google Scholar
• Kuhn W, Schmalfeldt B, Dose J, et al. Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study. Geburtshilfe Frauenheilkd 1996; 56: 105-10. (P1/36)
   Google Scholar
• Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncol-ogy Group study. J Clin Oncol 1998; 16: 405-10. (P1/82)
   Google Scholar
• Seymour MT, Mansi JL, Gallagher CJ, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191-5. (P1/47)
   Google Scholar
• de Wit R, van der Burg ME, van den Gaast, et al. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994; 5: 656-7. (P1/28)
   Google Scholar
• Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: anti-tumor activity and toxicity modification by liposomal encap-sulation. J Clin Oncol 1997; 15: 987-93. (P1/35)
   Google Scholar
• Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-3. (P1/50)
   Google Scholar
• Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: re-sponses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93. (P1/38)
   Google Scholar